Data are shown for fiscal years 2007 to 2013.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Mandawat A, Heidenreich PA, Mandawat A, Bhatt DL. Trends in Palliative Care Use in Veterans With Severe Heart Failure Using a Large National Cohort. JAMA Cardiol. 2016;1(5):617–619. doi:10.1001/jamacardio.2016.1687
Although palliative care (PC) improves quality of life in heart failure (HF),1-3 there is a paucity of data describing PC use in HF. The objective of this study was to describe trends in PC use in veterans with severe HF using a large national cohort.
We conducted a cross-sectional analysis of patients from fiscal years 2007 to 2013 using Veteran Affairs External Peer Review Program data. A detailed description of the Veteran Affairs External Peer Review Program has been previously published.4 The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) was used to select patients with a diagnosis of HF (codes 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93, and 428.x). Patients 70 years or older with brain-type natriuretic peptide levels exceeding 1000 pg/mL and creatinine levels exceeding 1.5 mg/dL were selected (to convert brain-type natriuretic peptide level to nanograms per liter, multiply by 1.0; creatinine level to micromoles per liter, multiply by 88.4). We indicated use if the patient was seen by PC (ICD-9-CM code V66.7) within 1 year after the index HF hospitalization. Patients with missing data, who accounted for less than 1.5% of data, were excluded. This study was approved by Stanford University’s Human Subjects Institutional Review Board.
Independent demographic variables included age, sex, and ethnicity. Clinical variables included laboratory values and comorbidities. The primary outcome was PC use. Bivariate analyses were performed using χ2 test and analysis of variance. Analyses of fiscal years were performed using Mantel-Haenszel test. Multivariable logistic regression models were used to determine adjusted predictors of PC use.
Over the 7-year period, 4474 patients with severe HF were identified. Among these patients, 7.6% (338 of 4474) were seen by PC. Compared with patients not seen by PC, those seen by PC were similar in age (mean [SD] age, 83.6 [6.4] vs 81.8 [6.2] years), were equally likely to be male (98.8% [334 of 338] vs 99.1% [4097 of 4136]), had a higher mean (SD) brain-type natriuretic peptide level (5260 [12 622] vs 4213  pg/mL), and had a similar percentage with left ventricular ejection fraction of less than 35% (44.7% [142 of 318] vs 46.7% [1790 of 3830]). Patients seen by PC had the following comorbidities coded in the prior 2 years: hypertension (93.2% [315 of 338]), chronic obstructive pulmonary disease (45.0% [152 of 338]), diabetes (48.5% [164 of 338]), cerebrovascular accident (29.9% [101 of 338]), malignancy (30.2% [102 of 338]), and acute myocardial infarction (26.6% [90 of 338]).
There was a significant trend toward increased PC use over time (Figure). Overall, 51.2% (2292 of 4474) of patients with HF died within 1 year of hospitalization. Those who died were more likely to have been seen by PC (10.7% [246 of 2292] vs 4.2% [92 of 2182], P < .001). Those seen by PC had a 1-year mortality of 72.8% (246 of 338) compared with 49.5% (2046 of 4136) among those who were not seen by PC (P < .001). On multivariable analysis, age, year, malignancy, and renal disease were significant predictors of PC use.
A strength of our study is an analysis of the largest integrated health care system (the Veteran Affairs Healthcare System) in the United States and an assessment of PC use up to 1 year after HF hospitalization. While use rates doubled during the study period, the absolute rate remained low (7.6% [338 of 4474]). Palliative care use in HF was specific (72.8% [246 of 338 of patients seen by PC died within 1 year) but not very sensitive (10.7% [246 of 2292] of patients who died within 1 year were seen by PC). Absolute rates of PC use in HF were less than the published rate in oncology (17%)5 and were similar to the published rate in chronic obstructive pulmonary disease (5.1%).6
This study has several limitations. We analyzed a predominantly male population in an integrated health care system, which may limit generalizability. We lacked data on symptoms or patient preference, which would influence which patients may qualify for PC. Errors in coding are possible, including overcoding or undercoding of PC use in HF. However, interrater reliability assessments are performed quarterly for each abstractor to ensure the accuracy of coding.4 Our rates of PC use in HF are consistent with prior single-center literature,1 suggesting external validity.
In conclusion, the use of PC in veterans with severe HF increased over the study duration, with absolute rates similar to chronic obstructive pulmonary disease and lower than cancer. Our data suggest the potential to improve use of PC in severe HF.
Corresponding Author: Deepak L. Bhatt, MD, MPH, Heart & Vascular Center, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115 (firstname.lastname@example.org).
Published Online: July 6, 2016. doi:10.1001/jamacardio.2016.1687.
Author Contributions: Dr Heidenreich had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: All authors.
Acquisition, analysis, or interpretation of data: Anant Mandawat, Heidenreich, Aditya Mandawat.
Drafting of the manuscript: Anant Mandawat.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Heidenreich.
Obtained funding: Heidenreich.
Administrative, technical, or material support: Anant Mandawat, Heidenreich, Aditya Mandawat.
Study supervision: Heidenreich.
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Bhatt reported serving on advisory boards for Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, and Regado Biosciences; reported serving on boards of directors for Boston Veterans Affairs Research Institute and the Society of Cardiovascular Patient Care; reported serving as chair of the American Heart Association quality oversight committee; reported serving on data monitoring committees for Duke Clinical Research Institute, Harvard Clinical Research Institute, Mayo Clinic, and Population Health Research Institute; reported receiving honoraria from the American College of Cardiology (senior associate editor of Clinical Trials and News and ACC.org), Belvoir Publications (editor in chief of Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), Harvard Clinical Research Institute (clinical trial steering committee), HMP Communications (editor in chief of Journal of Invasive Cardiology), Journal of the American College of Cardiology (guest editor and associate editor), Population Health Research Institute (clinical trial steering committee), Slack Publications (chief medical editor of Cardiology Today’s Intervention), Society of Cardiovascular Patient Care (secretary/treasurer), and WebMD (continuing medical education steering committees); reported serving on Clinical Cardiology (deputy editor), National Cardiovascular Data Registry–Acute Coronary Treatment and Interventions Outcomes Network Registry steering committee (vice-chair), and Veterans Affairs Clinical Assessment Reporting and Tracking research and publications committee (chair); reported receiving research funding from Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Forest Laboratories, Ischemix, Medtronic, Pfizer, Roche, Sanofi Aventis, and The Medicines Company; reported receiving royalties from Elsevier (editor of Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease); reported serving as a site coinvestigator for Biotronik, Boston Scientific, and St Jude Medical; reported serving as a trustee for the American College of Cardiology; and reported performing unfunded research for FlowCo, PLx Pharma, and Takeda. No other disclosures were reported.